SUBSEQUENT EVENTS (Details) (Subsequent event, USD $) In Millions, except Per Share data, unless otherwise specified	Jul. 30, 2013 item
Subsequent events
Number of separate merger agreements with public companies	2
Number of public companies with which merger agreement is entered	2
Trius Therapeutics, Inc. | Expected transaction
Subsequent events
Tender offer purchase price of outstanding common stock of acquiree (in dollars per share)	$ 13.50
Tender offer price for purchase of outstanding common stock of acquiree	$ 707
Number of contingent value rights receivable by stockholders of acquiree	1
Additional cash payment per share due to shareholders of acquiree, if certain sales milestones are achieved (in dollars per share)	$ 2.00
Total pending merger consideration	818
Optimer Pharmaceuticals, Inc.
Subsequent events
Amount agreed to be provided to acquiree per quarter to fund their operations in exchange for non-voting senior preferred stock	25
Maximum amount agreed to be provided to acquiree to fund their operations in exchange for non-voting senior preferred stock	75
Pending merger consideration for extinguishment of non-voting senior preferred stock	0
Fee payable by acquiree per quarter under the amended co-promotion agreement during the extended period	3.8
Fee payable by acquiree per year under the amended co-promotion agreement during the extended period	15
Amount that the entity is eligible to receive per quarter under the amended co-promotion agreement during the extended period, if certain sales and gross profit targets are achieved	3.1
Maximum amount that the entity is eligible to receive under the amended co-promotion agreement during the extended period, if certain sales and gross profits targets are achieved	12.5
Optimer Pharmaceuticals, Inc. | Expected transaction
Subsequent events
Tender offer purchase price of outstanding common stock of acquiree (in dollars per share)	$ 10.75
Tender offer price for purchase of outstanding common stock of acquiree	535
Number of contingent value rights receivable by stockholders of acquiree	1
Additional cash payment per share due to shareholders of acquiree, if certain sales milestones are achieved (in dollars per share)	$ 5.00
Total pending merger consideration	$ 801